Skip to content
2000
Volume 5, Issue 2
  • ISSN: 1871-5281
  • E-ISSN: 2212-4055

Abstract

There are several pre-clinical studies on the involvement of NO in inflammation. From this large amount of information it is clear that virtually every cell and many immunological parameters are modulated by NO. Thus, the final outcome is that NO cannot be rigidly classified as an anti-inflammatory or pro-inflammatory molecule. This peculiar aspect of the pathophysiology of NO has hampered the development of new drugs based on the concepts developed. Recent therapeutic approach are targeted to increase endogenous NO by activating the gene and some promising early data are available. At the present stage one of the most promising approach in the inflammation field is represented by a new class of NO-releasing compounds namely NO-NSAIDs that have recently enrolled in phase 2 clinical studies.

Loading

Article metrics loading...

/content/journals/iadt/10.2174/187152806776383143
2006-04-01
2025-10-26
Loading full text...

Full text loading...

/content/journals/iadt/10.2174/187152806776383143
Loading

  • Article Type:
    Research Article
Keyword(s): clinical data; inflammation; NO; NO-NSAIDs; pre-clinical data
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test